STERIS plc

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 1, 2026, Richard C. Breeden notified STERIS plc (the “Company”) that he will not stand for reelection to the Board of Directors (the “Board”) at the Company’s 2026 Annual General Meeting of Shareholders. Mr. Breeden’s decision to retire is not the result of any disagreement with the Company on any matters related to the Company’s operations, policies or practices. The Company and the Board thank Mr. Breeden for his 18 years of service to the Company as a Director. On May 5, 2026, the Board of the Company increased its size from nine to ten members and appointed Pierre Boulud to serve as a director effective as of that date. Mr. Boulud, age 54, is the Chief Executive Officer of bioMérieux, a biotechnology company focused on in vitro diagnostics, having served in that role since June 2023. Mr. Boulud joined bioMérieux in 2016 as Corporate Vice President, Head of Asia Pacific Region, and was promoted to Chief Operating Officer in 2020. Previously, he worked at Ipsen, a pharmaceutical company, from 2002 until 2016, serving in various roles of increasing responsibility and ultimately as the Executive Vice President of Specialty Care Commercial Operations. Mr. Boulud began his career as a strategic consultant, working at Bossard Consultants from 1995 to 1997 and at the Boston Consulting Group from 1997 to 2002. Mr. Boulud will receive a prorated fee of $76,989 for the remainder of the Board’s 2025-26 term of office, which will be payable in career restricted stock units granted in conjunction with the Company’s Non-Employee Director Compensation Program. Mr. Boulud will be eligible for the same indemnification program as the other members of the Board.

Item 7.01 Regulation FD Disclosure. On May 7, 2026, the Company issued a press release announcing Mr. Boulud’s appointment. The press release is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. Furthermore, the information contained in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933.